The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Dougie,
Totally agree, however. it does pose the question as to why no licensee has already committed to such given they have supposedly been in discussions since 2014 and the product has been on sale in Europe since Nov 2016 allowing them to get a few cans for their own testing (just need to send a local rep to a local doctor and fake the problem).
I would therefore hazard a guess that any licensee was only willing to pay peanuts and RPG (or whatever) were wanting a lot more. I do remember Dr Mike stating in a media interview some years back that they would not accept anything less than a billion USD, which, given the diabolical EU sales, understandably no one is willing to step up to the plate.
Announcements regarding licensees etc always seemed to say aim of taking place “ before or during phase 3 …” hopefully it’s smooth sailing to get through p2 then who knows … to a big pharma company it would be small change getting involved here with us and could be a gamble for them that pays off .
bignose pretty hard to imagine any potential licensing partners not doing their homework I'm afraid.much as i would love to hear positive news on the licensing front, i just don't see it happening until after FDA approval and then the question arises on what terms.could be wrong of course.still not clear what bothwell is referring to, or perhaps quoting from, nor what is meant by licensing partners. presumably means potential partners. anyway hope I'm wrong and that we get some news before the fda process is completed.
As much as I would love to agree with bothwell, we have been getting similar statements from announcements for a long long time with nothing coming to fruition
Ha ha ha...
Due to the deliberate spelling mistake, I read that as "panties" (have my google zoom set on low)...lol
Anyway, given that they were supposedly in talks with many panties (lol....) since 2014, what other information would they need ? Although the marketing data discusses price point and who would pay, it doesn't appear to address the most important factor of who actually will come out of the closet to buy the product. Have they actually performed an online survey of who would actually go to the doctors to buy the product, I certainly don't recall reading anything ? They can write whatever they want regarding 1 in 4 men suffer from it and how much the insurance companies are willing to spend etc etc, but surely none of it will create any reasonable license agreement if there are no market researched numbers. And if they use the EU numbers, well, we will certainly be up to our ears in 'dogs doo doo.
Its been far too long for RPG (or whatever) to try and pull the wool over the eyes of licensees who must have been watching the story unwind since 2014 and of course the lousy Chinese agreement wont help one little bit in fact its probably going to have quite the opposite effect.
Just my personal opinion based on history, incompetence etc etc.....but I could be wrong if the licensees have not done their homework.... :-)